FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051006006> ?p ?o ?g. }

• W2051006006 endingPage "156" @default.
• W2051006006 startingPage "151" @default.
• W2051006006 abstract "Objectives: We retrospectively assessed the combination of biweekly irinotecan with 5-fluorouracil (5-FU), and leucovorin (LV) as salvage chemotherapy in patients with advanced gastric cancer (AGC) previously treated with fluoropyrimidine (F), platinum (P), and taxane (T). Methods: Between October 2003 and February 2006, all 131 patients with AGC were treated with irinotecan (150 mg/m2 on day 1), along with either FOLFIRI-1 (ie, LV (20 mg/m2 bolus) before 5-FU (1000 mg/m2 continuous infusion over 6-hour) on days 1–2), or FOLFIRI-2 (ie, LV (20 mg/m2 bolus) before 5-FU (400 mg/m2 bolus) followed by 22-hour continuous infusion of 600 mg/m2 on days 1–2), or FOLFIRI-3 (ie, 5-FU (400 mg/m2 bolus) followed by 46-hour continuous infusion of 2400 mg/m2 5-FU and 100 mg/m2 LV). Cycles were repeated every 2 weeks. Results: The median age of the patients was 52 years (range, 19–70 years). Patients received a median of 4 cycles of chemotherapy (range, 1–21 cycles). Of the 97 patients with measurable disease, 1 (1.0%) achieved a complete response, and 11 (11.3%) achieved partial responses, making the overall response rate 12.3%. The median time to progression (TTP) was 2.2 months (95% CI, 1.9–2.6 months) and the median overall survival (OS) was 6.2 months (95% CI, 5.6–6.9 months). Good performance status (P = 0.046), fewer metastatic sites (P < 0.001), and longer time to progression of previous chemotherapy (P = 0.006) were independent prognostic factors affecting OS. OS was longer with the FOLFIRI-1 regimen but not with statistical significance (P = 0.064). The treatments were generally well tolerated. Conclusions: In actual clinical practice, biweekly irinotecan with 5-FU and LV had modest activity and tolerability in AGC patients previously treated with F, P, and T." @default.
• W2051006006 created "2016-06-24" @default.
• W2051006006 creator A5000363855 @default.
• W2051006006 creator A5004165781 @default.
• W2051006006 creator A5005925636 @default.
• W2051006006 creator A5014222628 @default.
• W2051006006 creator A5048561149 @default.
• W2051006006 creator A5063838757 @default.
• W2051006006 creator A5074535143 @default.
• W2051006006 creator A5085952795 @default.
• W2051006006 date "2008-04-01" @default.
• W2051006006 modified "2023-10-17" @default.
• W2051006006 title "Salvage Chemotherapy With Biweekly Irinotecan, Plus 5-Fluorouracil and Leucovorin in Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine, Platinum, and Taxane" @default.
• W2051006006 cites W1848862702 @default.
• W2051006006 cites W1910458543 @default.
• W2051006006 cites W1944693814 @default.
• W2051006006 cites W1969037111 @default.
• W2051006006 cites W1976651872 @default.
• W2051006006 cites W1981480220 @default.
• W2051006006 cites W1982559524 @default.
• W2051006006 cites W1992408996 @default.
• W2051006006 cites W2005461599 @default.
• W2051006006 cites W2012792853 @default.
• W2051006006 cites W2022746946 @default.
• W2051006006 cites W2068225833 @default.
• W2051006006 cites W2095355415 @default.
• W2051006006 cites W2095822339 @default.
• W2051006006 cites W2096139576 @default.
• W2051006006 cites W2105799699 @default.
• W2051006006 cites W2119071284 @default.
• W2051006006 cites W2122866527 @default.
• W2051006006 cites W2128447158 @default.
• W2051006006 cites W2169106066 @default.
• W2051006006 cites W2244827625 @default.
• W2051006006 cites W2269150820 @default.
• W2051006006 cites W2279052620 @default.
• W2051006006 cites W2288788326 @default.
• W2051006006 cites W2296894838 @default.
• W2051006006 cites W2314927739 @default.
• W2051006006 cites W2528428498 @default.
• W2051006006 doi "https://doi.org/10.1097/coc.0b013e31815878a2" @default.
• W2051006006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18391599" @default.
• W2051006006 hasPublicationYear "2008" @default.
• W2051006006 type Work @default.
• W2051006006 sameAs 2051006006 @default.
• W2051006006 citedByCount "29" @default.
• W2051006006 countsByYear W20510060062012 @default.
• W2051006006 countsByYear W20510060062014 @default.
• W2051006006 countsByYear W20510060062015 @default.
• W2051006006 countsByYear W20510060062016 @default.
• W2051006006 countsByYear W20510060062017 @default.
• W2051006006 countsByYear W20510060062018 @default.
• W2051006006 countsByYear W20510060062019 @default.
• W2051006006 countsByYear W20510060062020 @default.
• W2051006006 countsByYear W20510060062021 @default.
• W2051006006 countsByYear W20510060062022 @default.
• W2051006006 countsByYear W20510060062023 @default.
• W2051006006 crossrefType "journal-article" @default.
• W2051006006 hasAuthorship W2051006006A5000363855 @default.
• W2051006006 hasAuthorship W2051006006A5004165781 @default.
• W2051006006 hasAuthorship W2051006006A5005925636 @default.
• W2051006006 hasAuthorship W2051006006A5014222628 @default.
• W2051006006 hasAuthorship W2051006006A5048561149 @default.
• W2051006006 hasAuthorship W2051006006A5063838757 @default.
• W2051006006 hasAuthorship W2051006006A5074535143 @default.
• W2051006006 hasAuthorship W2051006006A5085952795 @default.
• W2051006006 hasConcept C121608353 @default.
• W2051006006 hasConcept C126322002 @default.
• W2051006006 hasConcept C141071460 @default.
• W2051006006 hasConcept C2776694085 @default.
• W2051006006 hasConcept C2776705615 @default.
• W2051006006 hasConcept C2777511904 @default.
• W2051006006 hasConcept C2780259306 @default.
• W2051006006 hasConcept C2780456651 @default.
• W2051006006 hasConcept C2781413609 @default.
• W2051006006 hasConcept C43376680 @default.
• W2051006006 hasConcept C526805850 @default.
• W2051006006 hasConcept C530470458 @default.
• W2051006006 hasConcept C71924100 @default.
• W2051006006 hasConcept C90924648 @default.
• W2051006006 hasConceptScore W2051006006C121608353 @default.
• W2051006006 hasConceptScore W2051006006C126322002 @default.
• W2051006006 hasConceptScore W2051006006C141071460 @default.
• W2051006006 hasConceptScore W2051006006C2776694085 @default.
• W2051006006 hasConceptScore W2051006006C2776705615 @default.
• W2051006006 hasConceptScore W2051006006C2777511904 @default.
• W2051006006 hasConceptScore W2051006006C2780259306 @default.
• W2051006006 hasConceptScore W2051006006C2780456651 @default.
• W2051006006 hasConceptScore W2051006006C2781413609 @default.
• W2051006006 hasConceptScore W2051006006C43376680 @default.
• W2051006006 hasConceptScore W2051006006C526805850 @default.
• W2051006006 hasConceptScore W2051006006C530470458 @default.
• W2051006006 hasConceptScore W2051006006C71924100 @default.
• W2051006006 hasConceptScore W2051006006C90924648 @default.
• W2051006006 hasIssue "2" @default.
• W2051006006 hasLocation W20510060061 @default.
• W2051006006 hasLocation W20510060062 @default.
• W2051006006 hasOpenAccess W2051006006 @default.

• next